Tricida Inc (TCDA) Insider Geoffrey M. Parker Acquires 5,000 Shares
Tricida Inc (NASDAQ:TCDA) insider Geoffrey M. Parker bought 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 13th. The stock was purchased at an average price of $29.72 per share, for a total transaction of $148,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of TCDA traded up $0.95 during trading hours on Tuesday, reaching $29.29. The stock had a trading volume of 64,900 shares, compared to its average volume of 162,752. Tricida Inc has a 12 month low of $21.87 and a 12 month high of $40.10.
Tricida (NASDAQ:TCDA) last issued its earnings results on Thursday, November 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.19. As a group, sell-side analysts forecast that Tricida Inc will post -3.12 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its position in Tricida by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 686,751 shares of the company’s stock valued at $20,981,000 after buying an additional 102,514 shares during the last quarter. United Services Automobile Association raised its position in Tricida by 30.8% in the 3rd quarter. United Services Automobile Association now owns 24,848 shares of the company’s stock valued at $759,000 after buying an additional 5,848 shares during the last quarter. American International Group Inc. purchased a new stake in Tricida in the 3rd quarter valued at $237,000. BlackRock Inc. raised its position in Tricida by 216.4% in the 3rd quarter. BlackRock Inc. now owns 1,005,103 shares of the company’s stock valued at $30,707,000 after buying an additional 687,414 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Tricida in the 3rd quarter valued at $1,057,000. Institutional investors own 62.48% of the company’s stock.
Tricida, Inc, a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease.
See Also: Rule of 72
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.